K von Appen

Suggest Changes
  • Citations Per Year
Learn More
  • K von Appen
  • IDrugs : the investigational drugs journal
  • 1999
Abgenix has acquired rights to ABX-CBL, an antibody in phase II trials for the potential treatment of graft versus host disease (GvHD). The antibody, previously known as CBL-1 was discovered by the(More)
  • K von Appen
  • IDrugs : the investigational drugs journal
  • 1999
RenaGel, developed by GelTex, is a polymer that binds and removes dietary phosphate from the intestinal tract without being absorbed into the bloodstream. A US NDA for control of hyperphosphatemia in(More)
  • 1